Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer

Pan, Bo; Che, Dehai; Cao, Jingyan; Shen, Jing; Shi, Jin; Zhou, Yi; Liu, Fang; Gu, Kuo; Man, Yingchun; Shang, Lihua; Yu, Yan

doi:10.3109/1354750x.2015.1068853

Cited by 29 publications

(33 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data were supported by work showing IL-17A to facilitate angiogenesis in lung cancer cell lines [55], and high circulating levels of IL-17 in NSCLC patients to be an independent bad prognostic factor [56]. A similar study by Yu and colleagues confirmed that serum levels of IL-17 are elevated and can be used as an independent prognostic factor in NSCLC [57].…”

Section: Il-17 Prognostic and Predictive Value In Lung Cancersupporting

confidence: 62%

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

Joerger

Finn

Cuffe

et al. 2016

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

There is strong pharmaceutical development of agents targeting the IL-17-TH17 pathway for the treatment of psoriasis (Ps) and psoriatic arthritis (PsA). Lung cancer accounts for 28% of all cancer-related deaths worldwide, and roughly 80% of patients with newly-diagnosed non-small cell lung cancer (NSCLC) present with metastatic disease, with a poor prognosis of around 12 months. Therefore, there is a high unmet medical need for the development of new and potent systemic treatments in this deadly disease. The emergence of immunotherapies such as anti-PD-1 or anti-PDL1 as candidate therapies in non-small cell lung cancer (NSCLC) indicates that targeting critical immuno-modulatory cytokines including those within the IL-17-Th1/Th17 axis may have proven benefit in the treatment of lung cancer. Areas covered: In this review we describe the current evidence for aberrant IL-17-Th1/Th17 settings in cancer, particularly with regard to targeting this axis in NSCLC. We further discuss the current agents under pharmaceutical development which could potentially target this axis, and discuss the current limitations and areas of concern regarding the use of these in lung cancer. Expert opinion: Current evidence suggests that moving forward agents targeting the IL-17-Th1/Th17 pathway may have novel new oncoimmunology indications in the treatment paradigm for NSCLC.

show abstract

Section: Il-17 Prognostic and Predictive Value In Lung Cancersupporting

confidence: 62%

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

Joerger

Finn

Cuffe

et al. 2016

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

show abstract

“…Cigarette smoking which is associated with over 80% of all lung cancers, recruits Th17 cells in the lungs (13,14), and has been associated with poor survival in NSCLC patients (15). Serum IL17A level is positively linked to vascular endothelial growth factor (VEGF) concentration in NSCLC patients, suggesting IL17A may promote angiogenesis in the tumor (16). Further, patients with high serum IL17A concentrations demonstrated a shorter overall survival rate compared with those with low levels (17).…”

Section: Pro-tumor Effect Of Il17amentioning

confidence: 99%

Lung Cancer Heterogeneity in Modulation of Th17/IL17A Responses

et al. 2019

View full text Add to dashboard Cite

The interplay between tumors and their immune microenvironment is critical for cancer development and progression. The discovery of tumor heterogeneity has provided a window into a complex interplay between tumors, their secreted products, and host immune responses at the cellular and molecular levels. Tumor heterogeneity can also act as a driving force in promoting treatment resistance and correlates with distinct tumor-mediated acquired immune responses. A prevailing question is how genetic aberrations in solid tumors can shape the immune landscape, resulting in pro-tumor or anti-tumor activities. Here we review evidence for clinical and pathophysiological mechanisms that underlie different types of non-small cell lung cancer (NSCLC) and provide new insights for future immunomodulatory-based therapies. Some of the more common driver mutations in NSCLC heterogeneity includes the opposing immune responses in oncogenic mutations in K-ras vs. non-K-ras models and their pro-inflammatory cytokines such as interleukin (IL)17A. We will discuss possible molecular and metabolic mechanisms that may govern the opposing immune responses observed in distinct genetic models of NSCLCs. A deeper understanding of how tumor heterogeneity modulates immune response can improve current therapeutic strategies and provide precise treatment to individual lung cancer patients.

show abstract

“…10 The presence of IL-17 and IL-17-expressing cells has recently been studied in several types of cancer, including NSCLC. [11][12][13][14][15][16] High serum IL-17 levels were detected in NSCLC patients and were significantly correlated with a late stage of NSCLC, overall survival (OS), and disease-free survival (DFS). [13][14][15] IL-17 in human NSCLC tissues was also significantly elevated and high IL-17 expression was significantly correlated with the clinical and pathological features of patients, such as TNM staging, OS and DFS.…”

Section: Introductionmentioning

confidence: 99%

“…[11][12][13][14][15][16] High serum IL-17 levels were detected in NSCLC patients and were significantly correlated with a late stage of NSCLC, overall survival (OS), and disease-free survival (DFS). [13][14][15] IL-17 in human NSCLC tissues was also significantly elevated and high IL-17 expression was significantly correlated with the clinical and pathological features of patients, such as TNM staging, OS and DFS. 11,12 In addition, the frequencies of IL-17-producing T cells (IL-17 + CD4 + Th17, IL-17 + CD8 + Tc17, and IL-17A + γδT17 cells) have been found to be dysregulated in NSCLS patients.…”

Section: Introductionmentioning

confidence: 99%

Long‐term prognostic significance of interleukin‐17‐producing T cells in patients with non‐small cell lung cancer

Wang

Chen

et al. 2019

Cancer Science

View full text Add to dashboard Cite

The presence of interleukin (IL)‐17‐producing T cells has recently been reported in non‐small cell lung cancer (NSCLC) patients. However, the long‐term prognostic significance of these populations in NSCLC patients remains unknown. In the present study, we collected peripheral blood from 82 NSCLC patients and 22 normal healthy donors (NC). Percentages of IL‐17‐producing CD4+T (Th17), CD8+T (Tc17) and γδT cells (γδT17) were measured to determine their association with clinical outcomes and overall survival (OS) in NSCLC. All NSCLC patients were followed up until July 2018. Median follow‐up time was 13.5 months (range 1‐87 months). The 3‐ and 5‐year survival rate was 27% and 19.6%, respectively. We found that Th17 cells and γδT17 cells were significantly increased, whereas Tc17 cells were markedly decreased in patients with NSCLC compared with those in NC. In addition, Th17 cells were significantly positively associated with T helper type 1 cells (Th1), whereas γδT17 cells were significantly negatively associated with γδT + interferon (IFN)‐γ+ cells. High percentages of peripheral Tc17 cells were significantly associated with favorable 5‐year OS (P = .025), especially in patients with early TNM stage (P = .016). Furthermore, high percentages of peripheral Th17 cells were positively associated with favorable 5‐year OS in patients with late TNM stage (P = .002). However, no significant association was observed between γδT17 cells and OS, regardless of the TNM stage. In conclusion, our findings suggest that enhanced Th17 and reduced Tc17 cells in the peripheral blood could be a significant predictor of a favorable prognosis for NSCLC patients.

show abstract

Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer

Abstract: IL-17 may play a role in NSCLC progression by promoting angiogenesis.

Cited by 29 publications

References 42 publications

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

Lung Cancer Heterogeneity in Modulation of Th17/IL17A Responses

Long‐term prognostic significance of interleukin‐17‐producing T cells in patients with non‐small cell lung cancer

Contact Info

Product

Resources

About